BlackRock MuniHoldings Investment Quality Fund (MFL) At $13.91 Forms Top; Catabasis Pharmaceuticals, Inc. (CATB) Had 4 Bullish Analysts

BlackRock MuniHoldings Investment Quality Fund (MFL) formed multiple top with $15.16 target or 9.00% above today’s $13.91 share price. BlackRock MuniHoldings Investment Quality Fund (MFL) has $525.91 million valuation. The stock increased 1.09% or $0.15 during the last trading session, reaching $13.91. About 172,019 shares traded or 29.96% up from the average. BlackRock MuniHoldings Investment Quality Fund (NYSE:MFL) has declined 3.95% since February 8, 2017 and is downtrending. It has underperformed by 20.65% the S&P500.

Among 5 analysts covering Catabasis Pharmaceuticals (NASDAQ:CATB), 4 have Buy rating, 0 Sell and 1 Hold. Therefore 80% are positive. Catabasis Pharmaceuticals had 14 analyst reports since August 17, 2015 according to SRatingsIntel. The stock of Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) earned “Buy” rating by Citigroup on Tuesday, March 22. On Thursday, June 9 the stock rating was maintained by Citigroup with “Buy”. Cowen & Co maintained it with “Hold” rating and $200 target in Thursday, August 10 report. The company was maintained on Wednesday, June 8 by Wedbush. The company was maintained on Monday, August 14 by Oppenheimer. Wedbush maintained the shares of CATB in report on Monday, August 17 with “Buy” rating. Cowen & Co maintained Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Thursday, October 5 with “Hold” rating. The stock has “Neutral” rating by Citigroup on Thursday, October 5. H.C. Wainwright initiated Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) on Thursday, December 22 with “Buy” rating. The rating was upgraded by Citigroup on Monday, November 20 to “Buy”. See Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) latest ratings:

20/11/2017 Broker: Citigroup Rating: Buy New Target: $2.5 Upgrade
05/10/2017 Broker: Cowen & Co Rating: Hold New Target: $2.0 Maintain
05/10/2017 Broker: Citigroup Rating: Neutral Old Target: $1.5 New Target: $3.5 Maintain
29/09/2017 Broker: Citigroup Rating: Hold New Target: $1.5
14/08/2017 Broker: Wedbush Rating: Buy Maintain
14/08/2017 Broker: Oppenheimer Rating: Buy New Target: $4.0000 Maintain
14/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $9.2900 Maintain
10/08/2017 Broker: Cowen & Co Rating: Hold New Target: $2.0000 Maintain

Investors sentiment decreased to 1 in Q3 2017. Its down 0.27, from 1.27 in 2017Q2. It worsened, as 6 investors sold BlackRock MuniHoldings Investment Quality Fund shares while 9 reduced holdings. 3 funds opened positions while 12 raised stakes. 4.70 million shares or 6.25% less from 5.02 million shares in 2017Q2 were reported. Moreover, Provise Group Inc Limited Liability has 0.04% invested in BlackRock MuniHoldings Investment Quality Fund (NYSE:MFL). Invest Advsrs Ltd Liability Corporation reported 85,329 shares. Cambridge Invest Advsrs reported 20,849 shares. Stifel Fincl invested 0% in BlackRock MuniHoldings Investment Quality Fund (NYSE:MFL). Fifth Third Bankshares holds 0% of its portfolio in BlackRock MuniHoldings Investment Quality Fund (NYSE:MFL) for 2,692 shares. Moreover, Invesco Limited has 0% invested in BlackRock MuniHoldings Investment Quality Fund (NYSE:MFL) for 77,299 shares. Hollencrest Ltd Com reported 28,140 shares stake. Raymond James Advisors, a Florida-based fund reported 27,605 shares. Sit Inv Inc reported 0.1% of its portfolio in BlackRock MuniHoldings Investment Quality Fund (NYSE:MFL). Royal Financial Bank Of Canada holds 311,970 shares. First Trust L P owns 0% invested in BlackRock MuniHoldings Investment Quality Fund (NYSE:MFL) for 76,569 shares. The Illinois-based Guggenheim Ltd Liability Company has invested 0.01% in BlackRock MuniHoldings Investment Quality Fund (NYSE:MFL). Virtu Financial Limited Liability Com stated it has 14,149 shares. Cohen Steers owns 94,138 shares. Hightower Advsrs Limited Company reported 0.02% stake.

Catabasis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic products based on safely metabolized and rationally targeted linker drug discovery platform in the United States. The company has market cap of $30.24 million. The firm offers Edasalonexent, an investigational oral small molecule, which is in Phase I/II clinical trial for the treatment of duchenne muscular dystrophy (DMD). It currently has negative earnings. It is also involved in developing SMART linker conjugates that are in preclinical stage of development, including CAT-5571 for cystic fibrosis (CF) trafficking and function of CF transmembrane conductance regulator, as well as for the clearance of Pseudomonas aeruginosa; and CAT-4001 for the treatment of severe and rare neurodegenerative diseases, such as Friedreich's ataxia and amyotrophic lateral sclerosis.

It closed at $1.31 lastly. It is down 73.74% since February 8, 2017 and is downtrending. It has underperformed by 90.44% the S&P500.